

COMING SOON!

Pre-Register Now for the new PHA Online University www.PHAOnlineUniv.org

Through the PHA Online University, physicians, nurses and other health care providers will be able to access the latest information on pulmonary hypertension, engage in networking and discussion amongst colleagues worldwide, and earn free online CME/CEU credits.

Please visit the site at www.PHAOnlineUniv.org to learn more. If you would like to be alerted when the site goes live, please e-mail PHAOnlineUniv@PHAssociation.org.

 **PHA** ONLINE UNIVERSITY
A Program of the Pulmonary Hypertension Association Medical Education Fund

16. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. *J Am Coll Cardiol*. 2006;47(10):2049-2056.

17. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol*. 2003;41(12):2119-2125.

18. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J*. 2005;25(2):244-249.

19. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. *Eur Respir J*. 2006;28(6):1195-1203.

20. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. *Eur Heart J*. 2006;27(5):589-595.

21. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *J Am Coll Cardiol*. 2003;42(1):158-164.

22. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J*. 2004;24(3):353-359.

23. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2006;174(11):1257-1263.

24. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2006;28(4):691-694.

25. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med*. 2008;149(8):521-530.

26. Mereles D, Ehlken N, Kreuzer S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation*. 2006;114(14):1482-1489.

27. McLaughlin V, Rubin L, Benza R, et al. TRIUMPH I: Efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH). *Am J Respir Crit Care Med*. 2008;177:A965.

29. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet*. 2008;371(9630):2093-2100.

30. Frost AE, Langleben D, Oudiz R, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. *Vascul Pharmacol*. 2005;43(1):36-39.

31. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. *Chest*. 2006;130(4):1198-1202.

32. McLaughlin VV. 'Raising the bar' for the treatment of pulmonary arterial hypertension. *Eur Heart J*. Mar 2006;27(5):510-511. ■